Digoxin

Specifications / Handling

More Information
Product Details
Synonyms	12β-Hydroxydigitoxin; NSC 95100
Product Type	Chemical
Properties
Formula	C₄₁H₆₄O₁₄
MW	780.94
CAS	20830-75-5
Source/Host Chemicals	Synthetic.
Purity Chemicals	≥95% (HPLC)
Appearance	White powder.
Solubility	Soluble in DMSO (100mM) or methanol.
Identity	Determined by NMR.
Declaration	Manufactured by Chemodex.
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key	LTMHDMANZUZIPE-PUGKRICDSA-N
Smiles	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry. Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Cardiac glycoside from the leaves of Digitalis lanata. It is used to treat cardiac arrhythmias. It is often used as a model substrate of P-glycoprotein (Pgp) (0.01-10µM) and an inhibitor of Na+/K+-ATPase. Inhibits membrane-bound α-subunits of the Na+/K+ ATPase pump in myocytes. The primary mechanism of action involves inhibition of the Na+/K+ ATPase, mainly in the myocardium. This inhibition causes an increase in intracellular sodium levels, resulting in a reversal of the action of the sodium-calcium exchanger, which causes an increase in the intracellular calcium concentration. This leads to a decrease in heart rate and increased storage of calcium in the sarcoplasmic reticulum, causing a corresponding increase in the release of calcium during each action potential.

Product References

(1) R.G. Woolfson, et al.; Kidney Int. 46, 297 (1994) | (2) S. Reddy, et al.; Curr. Opin. Cardiol. 12, 233 (1997) | (3) K. Kjeldsen & H. Bundgaard; Ann. N Y Acad. Sci. 986, 702 (2003) | (4) M. Gheorghiade, et al.; Circulation 109, 2959 (2004) | (5) M. Ehle, et al.; Crit. Pathw. Cardiol. 10, 93 (2011) | (6) R.J. Biggar; Clin. Cancer Res. 18, 2133 (2012) | (7) A.M. Nader & D.R. Foster; J. Clin. Pharmacol. 54, 3 (2014) | (8) G.A. Ewy; Am. J. Med. 128, 1272 (2015)

Call	+41 61 926 6040
Fax	+41 61 926 6049